Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Jodi B Segal(Johns Hopkins University), Catalina Suarez‐Cuervo(University of North Carolina at Chapel Hill), David R. Nelson(Harvard University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Michael Fried(University of North Carolina at Chapel Hill)
Cited by 111
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728